Abstract
Background The platelet-to-lymphocyte ratio (PLR) is a promising inflammatory biomarker contributing to the development of atherosclerosis and type 2 diabetes mellitus (T2DM). Therefore, this study aims to document the value of PLR in predicting adverse events in patients undergoing percutaneous coronary intervention (PCI) with and without T2DM.
Methods This study consecutively enrolled 8831 patients who received PCI, and we divided them into 4 groups according to the PLR level and glycemic metabolic statuses (PLR-low/high with non-T2DM, PLR-low/high with T2DM). The endpoints were major adverse cardiovascular and cerebrovascular events (MACCE) and stent thrombosis. Multivariate COX regression analysis was used to determine the association.
Results During the 2.4-year follow-up, a total of 663 (7.5%) MACCE and 75 (0.85%) stent thrombosis were recorded. Results showed that patients with high PLR levels presented a significantly higher risk of MACCE (HR: 1.26, 95%CI: 1.07 to 1.47, P = 0.005) and stent thrombosis (HR: 2.29, 95%CI, 1.39 to 3.79, P = 0.001) when compared with the PLR-low group. When focused on patients with T2DM, the PLR-high group showed a significantly higher risk of MACCE (HR: 1.53, 95%CI: 1.17 to 2.00, P = 0.002) and stent thrombosis (HR: 3.79, 95%CI, 1.62 to 8.86, P = 0.002). However, these associations were not significant in patients without T2DM.
Conclusions For the first time, PLR is documented as a great predictor for the poor prognosis and high incidence of stent thrombosis in patients with CAD, especially in those with T2DM.
What Is New?
In patients undergoing percutaneous coronary intervention (PCI), high serum platelet-to-lymphocyte ratio (PLR) is associated with poor prognosis and a high risk of stent thrombosis.
When focusing on patients with different glycemia statuses, we found that the predictive value of PLR for poor prognosis and high risk of stent thrombosis was significant in patients with type 2 diabetes mellitus (T2DM), but not in patients without T2DM.
Among patients with different PLR levels and glycemia statuses, those combined with both high PLR levels and T2DM showed the highest risk of poor prognosis and stent thrombosis.
In stent thrombosis events, very late stent thrombosis is the most common type in patients with high PLR.
What Are the Clinical Implications?
Patients undergoing PCI with high PLR levels should be monitored closely.
Residual inflammation should be focused among patients with coronary heart disease after revascularization to improve the long-term prognosis.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
None
Funding Statement
This study is supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-008).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research process was following the Declaration of Helsinki and was approved by the Institutional Review Board of Fuwai Hospital, Chinese Academy of Medical sciences. All subjects provided informed written consent for long-term follow-up before intervention.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
The datasets used during the current study are available from the corresponding author upon reasonable request.
List of abbreviations
- ACS
- acute coronary syndrome
- AST
- acute stent thrombosis
- BMI
- body mass index
- CAD
- coronary artery disease
- CCS
- Chronic coronary syndrome
- CTO
- chronic total occlusion
- CI
- confidence interval
- CABG
- coronary artery bypass grafting
- CCC
- coronary collateral circulation
- DES
- drug-eluting stents
- DAPT
- dual anti-platelet therapy
- hsCRP
- high-sensitivity C-reactive protein
- HbA1c
- glycosylated hemoglobin A1c
- K-M
- Kaplan-Meier
- LDL-C
- low-density lipoprotein cholesterol
- LM
- left main artery disease
- LVEF
- left ventricular ejection faction
- LST
- late stent thrombosis
- MI
- myocardial infarction
- MACCE
- major adverse cardiovascular and cerebrovascular events
- PCI
- percutaneous coronary intervention
- PLR
- platelet-to-lymphocyte ratio
- PAD
- peripheral artery disease
- STEMI
- ST-elevation myocardial infarction
- SD
- standard deviation
- SAST
- subacute stent thrombosis
- T2DM
- type 2 diabetes mellitus
- TC
- total cholesterol
- TG
- triglyceride
- TIMI
- thrombolysis in myocardial infarction
- VLST
- very late stent thrombosis.
